MicroRNA-29a regulates lipopolysaccharide (LPS)-induced inflammatory responses in murine macrophages through the

Bufu Tang1, Xingchen Li2, Yanling Ren1

  • 1First Affiliated Hosp Dalian Med Univ, Dept Oncol, Dalian 116011, PR China.

Insights

MicroRNA-29a (miR-29a) amplifies inflammatory responses in macrophages stimulated by lipopolysaccharide (LPS). It targets Akt1, enhancing NF-κB signaling and promoting pro-inflammatory cytokine release.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Macrophage activation by lipopolysaccharide (LPS) involves inflammatory signaling pathways.
  • MicroRNAs (miRNAs) regulate gene expression and play roles in immune responses.
  • Akt signaling is implicated in inflammatory processes.

Purpose of the Study:

  • To investigate the role of miR-29a in lipopolysaccharide (LPS)-induced inflammatory responses in macrophages.
  • To elucidate the molecular mechanism by which miR-29a influences inflammatory signaling.

Main Methods:

  • Primary macrophages and RAW264.7 cells were stimulated with LPS.
  • miR-29a levels were measured using quantitative real-time PCR.
  • Overexpression and knockdown of miR-29a were performed.
  • Bioinformatics analyses identified potential miRNA targets.
  • Western blotting assessed protein phosphorylation and expression.
  • NF-κB transcriptional activity was measured.

Main Results:

  • LPS stimulation increased miR-29a levels in a dose-dependent manner.
  • Overexpression of miR-29a enhanced IL-1β and IL-6 expression, while knockdown diminished it.
  • Akt1 was identified as a direct target of miR-29a.
  • miR-29a promoted LPS-induced NF-κB signaling by increasing p65 phosphorylation and NF-κB transcriptional activity via Akt1.
  • Akt1 silencing mimicked the effects of miR-29a overexpression on cytokine expression and NF-κB pathway activation.

Conclusions:

  • miR-29a acts as a positive regulator of inflammatory responses in LPS-stimulated macrophages.
  • The mechanism involves miR-29a targeting Akt1, leading to enhanced NF-κB pathway activation.
  • These findings highlight miR-29a as a potential therapeutic target for inflammatory diseases.